News

Empower Announces AI Pilot Program

Feb 5, 2019 | Press Releases

Empower is commencing a pilot program with Datametrex AI to identify potential improvements and analyze efficacy in long-term patient care

VANCOUVER BC: February 5, 2019 – EMPOWER CLINICS INC. (CSE: EPW) (Frankfurt

8EC)  (“Empower”  or  the  “Company”)  today  announces  it  intends  to  partner  with Datametrex AI Limited (“Datametrex”) and its subsidiary, Canntop AI Inc. (“Canntop”), to create  a  pilot  program  that  uses  Artificial  Intelligence  (AI)  to  analyze  and  gain  insights about Empower patient data, physician treatment recommendations and overall long-term efficacy of patient care.

The Company further intends to use Canntop’s AI platform to gain actionable insights on how  consumer  social  data  is  generating  nationwide  interest  in  CBD  based  products, alternative pain management options and the use of cannabis-based therapies.

The pilot program is expected to utilize Empower patient data in a HIPAA compliant manner, to  determine  if  normalized  data  can  be  generated  using  Datametrex  AI  solutions  to understand how patient care and efficacy of physician-guided treatment recommendations are positively impacting serious qualifying conditions of patients.

“We  believe  using  AI  tools  to  analyze  the  substantial  amounts  of  data  in  the  Empower database  and  the  additional  data  from  the  recently  announced  proposed  Sun  Valley acquisition can make Empower a data science leader in the cannabis industry,” said Steven McAuley, Empower’s Chief Executive Officer. “We believe the outcomes of our AI efforts, if successful, could position the Company as an educational leader and we plan to collaborate with the industry to ultimately improve patient care.”

“Datametrex has already utilized its Nexalogy AI solution for Health Canada studies in the cannabis  sector  to  understand  consumer  usage  and  patterns  based  on  massive  social insights  generated  through  channels  like  Twitter,  Facebook,  Instagram  and  others,”  said Jeffrey Stevens, Datametrex President & COO. “We believe an AI pilot with Empower has the  potential  to  provide  disruptive  insights  about  alternative  care  options  that  can  be provided to people around the world.”

 

EMPOWER TECHNOLOGY

  • Patient EHR and Management System Empower utilizes a market-leading patient electronic management and POS system that is HIPAA compliant and provides deep insight to patient care.
  • Tele-Medicine Platform  The  Company  supports  remote  patients  using  its  tele- medicine portal, enabling patients who do not live near one of its clinic locations, or are  disabled  or  unable  to  come  to  a  location,  to  still  benefit  from  a  doctor consultation.
  • Website and  e-commerce  Empower  will  be  commencing  the  development  of  its new corporate website and e-commerce store to promote and sell its growing line of CBD based products under the Sollievo brand and other partner brands.

The Company also announces the resignation of Carly Krivanek as Chief Financial Officer. Mr. McAuley will act as interim Chief Financial Officer until such time as the Company has identified a suitable candidate to fill the position. The Company thanks Ms. Krivanek for her contributions and wishes her well with her future endeavors.

ABOUT EMPOWER

Empower  is  undertaking  new  growth  initiatives  to  position  itself  as  a  diverse,  vertically integrated  health  and  wellness  company,  with  an  expanding  network  of  physician-staffed clinics and a diverse cannabidiol (CBD) product strategy, and as a leader in hemp-derived CBD extraction, research and development. The Company’s treatment solutions are focused on  education,  data  and  efficacy  in  combination  with  other  modalities  to  support  patients with  serious  qualifying  conditions,  such  as  chronic  pain,  PTSD,  sleep  disorders,  opioid dependency,  epilepsy  and  more.  It  is  expected  that  Empower’s  proprietary  product  line “Sollievo”  will  offer  patients  a  variety  of  delivery  methods  of  doctor  recommended  CBD- based  product  options  in  its  clinics,  online  and  at  major  retailers.  With  over  120,000 patients, an expanding clinic footprint, a focus on new technologies, including tele-medicine, and  an  expanded  product  development  strategy,  Empower  is  ready  to  capitalize  on  the market  growth  expectations  in  the  United  States  after  the  passing  of  US$867  billion Agriculture Improvement Act (the Farm Bill).

 

ON BEHALF OF THE BOARD OF DIRECTORS:

 

Steven McAuley

Chief Executive Officer

CONTACTS: Steve Low

Boom Capital Markets

steve@boomcapitalmarkets.com

647-620-5101

 

Steven McAuley, CEO

s.mcauley@empowerclinics.com

604-789-2146

 

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This  news  release  contains  certain  “forward-looking  statements”  or  “forward-looking  information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on  expectations,  estimates  and  projections  as  at  the  date  of  this  news  release.  Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”,  “believes”,  “anticipates”,  “estimates”,  “may”,  “will”,  “potential”,  “proposed”  and  other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include, but are not limited to, statements regarding: the proposed pilot program with Datametrex and Canntop; the intended goals and objectives of the program; that the program will use patient data in a HIPAA compliant manner; that the use of AI could make the Company a data science leader in the cannabis industry and position the Company as an educational leader; that the program will help the industry improve patient care; the Company’s proposed new website   and   e-commerce   store;   and   the   Company’s   ability   to   capitalize   on   market   growth expectations. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including:

that the Company may be unable to develop a program that is HIPAA compliant; cybersecurity risks; that the Company may not realize the expected benefits of the program; that the program may not cause the Company to become an educational or data science leader; that legislative changes may have an adverse affect on the Company’s business and product development, including the Company’s ability to launch the pilot program; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated  by  the  forward-looking  statements  will  occur  or,  if  they  do  occur,  what  benefits  the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward- looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

Categories

COVID-19 Testing is Now Available.

X